Institutional Review Board, Hospital for Special Surgery
March 11, 2019
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Jessica R. Berman, MD
John A. Carrino, MD, MPH
Jackie Finik
Kyriakos A. Kirou, MD, DSc, FACP
Sarah Lieber, MD
Stephen A. Paget, MD
Lisa R. Sammaritano, MD
Dina Sheira
Number of patients: 70
Enrollment period: Ongoing; anticipated completion 6/30/19
Duration of follow-up: 1 year
Inclusion criteria:
Exclusion criteria:
Sarah Lieber, MD
liebers@hss.edu
212.774.2482